Prospects for Higgs Searches via VBF at the LHC with the ATLAS Detector

We report on the potential for the discovery of a Standard Model Higgs boson with the vector boson fusion mechanism in the mass range 115 with the ATLAS experiment at the LHC. Feasibility studies at hadron level followed by a fast detector simulation have been performed for H\to W^{(*)}W^{(*)}\to l^+l^-\sla{p_T}, $H\to\gamma\gamma$ and $H\to ZZ\to l^+l^-q\bar{q}$. The results obtained show a large discovery potential in the range 115. Results obtained with multivariate techniques are reported for a number of channels.Comment: 14 pages, 4 figures, contributed to 2003 Les Houches Workshop on Physics at TeV Colliders. Incorporated comments from ATLAS referee

Ground state properties of one-dimensional Bose-Fermi mixtures

Bose-Fermi mixtures in one dimension are studied in detail on the basis of an exact solution. Corresponding to three possible choices of the referecce state in the quantum inverse scattering method, three sets of Bethe-ansatz equations are derived explicitly. The features of the ground state and low-lying excitations are investigated. The ground state phase diagram caused by the external field and chemical potential is obtained

Study of color connections in e+e−e^+ e^- annihilation

We replace in the event generator JETSET the color singlet chain connection with the color separate state one as the interface between the hard and soft sectors of hadronic processes. The modified generator is applied to produce the hadronic events in $e^+ e^-$ annihilation. It describes the experimental data at the same level as the original JETSET with default parameters. This should be understood as a demonstration that color singlet chain is not the unique color connection. We also search for the difference in special sets of three-jet events arising from different color connections, which could subject to further experimental test.Comment: 23 pages, 8 figures, 4 tables, Revtex

Polo-like kinase 1 siRNA-607 induces mitotic arrest and apoptosis in human nasopharyngeal carcinoma cells

Polo-like kinase (Plk) 1 is overexpressed in many human malignancies including nasopharyngeal carcinoma, indicating its potential as a therapeutic target. Recently, using a simple cellular morphologybased strategy, we have identified several novel effective siRNAs against Plk1 including Plk1 siRNA- 607. In this study, we further investigated the effects of Plk1 siRNA-607 in human nasopharyngeal carcinoma cell line, HNE-1. Real time RT-PCR and Western blot indicated that Plk1 siRNA-607 transfection resulted in a significant inhibition in Plk1 expression in the HNE-1 cells. Furthermore, cell cycle, cell growth and apoptosis analysis clearly indicated that Plk1 siRNA-607 caused a dramatic mitotic cell cycle arrest followed by massive apoptotic cell death, and eventually resulted in a significant decrease in growth and viability of the nasopharyngeal carcinoma cells. Given that Plk1 has been widely accepted as a novel efficient target for cancer therapy, these results suggested that Plk1 siRNA-607 could be further developed for the treatment of human nasopharyngeal carcinoma.Key words: Nasopharyngeal carcinoma, Plk1, RNA silencing, cell cycle, apoptosis

Comparison of Infection Risks Between Various Inhaled and Intranasal Corticosteroids: A Pharmacovigilance Analysis Based on the FAERS Database

Ying Lan,1 Die Hu,1 Shijing Huang,1 Qing Ma,1 Li Chen,2,3 Min Xu,1 Qin He1 1Department of Pharmacy, Affiliated Hospital of Southwest Jiaotong University, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, 610031, People’s Republic of China; 2Department of Pharmacology, Faculty of Medicine, University of the Basque Country, UPV/EHU, Leioa, Spain; 3Department of Pharmacy and Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of ChinaCorrespondence: Ying Lan; Li Chen, Email [email protected]; [email protected]: This study conducted a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database to compare the infection risk of inhaled or nasal Beclomethasone, Fluticasone, Budesonide, Ciclesonide, Mometasone, and Triamcinolone Acetonide.Methods: We used proportional imbalance analysis to evaluate the correlation between ICS /INCs and infection events. The data was extracted from the FAERS database from April 2015 to September 2023. Further analysis was conducted on the clinical characteristics, site of infection, and pathogenic bacteria of ICS and INCs infection adverse events (AEs). We used bubble charts to display their top 5 infection adverse events.Results: We analyzed 21,837 reports of infection AEs related to ICS and INCs, with an average age of 62.12 years. Among them, 61.14% of infection reports were related to females. One-third of infections reported to occur in the lower respiratory tract with Fluticasone, Budesonide, Ciclesonidec, and Mometasone; over 40% of infections reported by Triamcinolone Acetonide were eye infections; the rate of oral infections caused by Beclomethasone were 7.39%. The reported rates of fungal and viral infections caused by beclomethasone were 21.15% and 19.2%, respectively. The mycobacterial infections caused by Budesonide and Ciclesonidec account for 3.29% and 2.03%, respectively. Bubble plots showed that the ICS group had more fungal infections, oral infections, pneumonia, tracheitis, etc. The INCs group had more eye symptoms, rhinitis, sinusitis, nasopharyngitis, etc.Conclusion: Women who use ICS and INCs are more prone to infection events. Compared to Budesonide, Fluticasone seemed to have a higher risk of pneumonia and oral candidiasis. Mometasone might lead to more upper respiratory tract infections. The risk of oral infection was higher with Beclomethasone. Beclomethasone causes more fungal and viral infections, while Ciclesonide and Budesonide are more susceptible to mycobacterial infections.Keywords: data mining, FAERS, ICS, INCs, pharmacovigilance, infection